Gradient Denervation Technologies < Back
Gradient Denervation Technologies is developing a novel intravascular, catheter-based technology to treat pulmonary hypertension, a fatal condition that affects approximately 500,000 patients per year worldwide. This disruptive therapy aims at reducing pulmonary vascular resistance and improving cardiovascular hemodynamics.
Feasibility of this approach has been demonstrated through published literature. Our goal at Gradient is to develop a device completely optimized for this indication, providing homogenous and durable results.
Gradient Denervation Technologies is currently getting ready for first-in-human following a successful seed financing round and prototyping phase.
